PER

1.35%

7.5¢ percheron therapeutics limited

Anna, Kudos to your research skills - where did you find that...

First 152 Last

Share
Profile

Follow
Uboy

4,683 Posts.

1086

10/06/21

15:55

Post #: 53772773
Share

Originally posted by Vinceanna ↑

Alzheimer’s Decision Sends Positive Message to Aussie Biotechs

This is from Dr.G. Price Point of view:

A prominent US physician and consultant to Antisense Therapeutics (ASX:ANP), Dr Gil Price notes the FDA’s approval was based on complex data set. That being the case, Biogen will conduct a controlled trial for the verification of Aduhelm clinical benefit in patients with AD.

“But if Antisense Therapeutics produces similar data, we would expect a similar decision from FDA,” says Price, a former director of the Nasdaq-listed Duchenne muscular dystrophy (DMD) drug developer Sarepta Therapeutics.

Antisense is is planning to pursue FDA “fast track” designation for its DMD drug candidate ATL1102. DMD is an incurable muscle wasting disorder that affects one in every 3600 to 6000 male children.

The company is currently discussing the construct of a proposed phase 2b/3 trial with the FDA.

However Price says the FDA’s decision does not constitute a lowering of standards. “The FDA reviewed data in a very difficult therapeutic area, and made a reasonable decision that offers patients hope,” he says.

“Keep in mind that FDA has been working with Biogen over the past 10 years as a partner, more than an overseer.“

Antisense Therapeutics appreciates the culture at FDA for the development of drugs that treat rare diseases and hopes to build a similar relationship as we continue to move forward.”

Expand

Anna,

Kudos to your research skills - where did you find that nugget?

Most of us here rate Dr Price highly...he is thick with FDA / Janet...from his previous Sarepta days.

Every time Price, Gittleson or Goolsbee are quoted in the press...the value of any 'partnership' deal goes up

The science is great - but the science alone will not get the best ROI for shareholders.

Can't wait for the new indications anns.

Alzheimers, Asthma, GLMD.......

Can't be long now.

Last edited by Uboy: 10/06/21

ANP Price at posting: 22.5¢ Sentiment: Buy Disclosure: Held
21 Upvote

0 Great analysis

Reply

Top Stories

HRZ

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

NVA

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

IGO

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

ASX Market Open: ASX200 to rise for Friday session | July 26

RHK

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

MIN

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

MND

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Nine's staff strike as Paris Olympic coverage begins

There are more pages in this discussion • 40 more messages in this thread...

First 152 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.5¢		Change 0.001(1.35%)		Mkt cap ! $67.61M

Open	High	Low	Value	Volume
7.7¢	7.8¢	7.4¢	$24.63K	325.4K

Buyers (Bids)

No.	Vol.	Price($)
2	142779	7.3¢

Sellers (Offers)

Price($)	Vol.	No.
7.5¢	8181	1

View Market Depth

No.	Vol.	Price($)
2	142779	0.073
2	147362	0.072
2	310000	0.071
4	34299	0.070
2	28980	0.069

Price($)	Vol.	No.
0.075	8181	1
0.078	125476	3
0.079	175123	2
0.080	287231	3
0.081	125000	2

Last trade - 16.10pm 26/07/2024 (20 minute delay)

PER (ASX) Chart

Anna, Kudos to your research skills - where did you find that...

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

ASX Market Open: ASX200 to rise for Friday session | July 26

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Nine's staff strike as Paris Olympic coverage begins

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Anna, Kudos to your research skills - where did you find that...

Top Stories

Horizon firms up ore reserve for Boorara ahead of FY25 Q1 development decision

Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter

IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity

ASX Market Open: ASX200 to rise for Friday session | July 26

Red Hawk upgrades Blacksmith with DSO mineral resource at the Eagle Deposit

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

MinRes jumps 5% as the company meets production guidance – depressed iron ore prices be damned

Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Nine's staff strike as Paris Olympic coverage begins

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News